Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043935 | 0.87 | BACE1 (0.36) | MAPTRXFP1MEN1KMT2AGAA | |
| SCHEMBL6043692 | 0.85 | MAPT (0.36) | MAPTRXFP1MEN1KMT2AKDM4E | |
| SCHEMBL6044403 | 0.85 | LMNA (0.37) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6044320 | 0.85 | SMN1; SMN2 (0.35) | MAPTMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL6043053 | 0.79 | BACE1 (0.38) | — | |
| SCHEMBL6044088 | 0.79 | BACE1 (0.37) | — | |
| SCHEMBL6044446 | 0.79 | BACE1 (0.37) | — | |
| SCHEMBL6044129 | 0.79 | BACE1 (0.36) | — | |
| SCHEMBL6044731 | 0.77 | BACE1 (0.35) | — | |
| SCHEMBL6044685 | 0.76 | NTRK1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | claimed |
| EP-1430032-A2 | SUBSTITUTED AMIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Elan Pharmaceuticals, Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2003027068-A2 | SUBSTITUTED AMINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2003-04-03 | — | — | WO | claimed |
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | BACE1, APP, BACE2 | MAPT 27/4885RXFP1 3176/4885MEN1 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.